Opioid Maker Indivior pays $102.5M to settle opioid antitrust claims’ antitrust claims involving treatment for opioid addiction in litigation brought by more than 42 state attorneys general.
Regulators said that Indivior’s practices suppressed the market for generic versions of the drug, Suboxone.
Opioid Maker Indivior pays $102.5M to settle opioid antitrust claims
Opioid Maker Indivior pays $102.5M to settle opioid antitrust claims
“As the opioid crisis was raging across the country, Indivior selfishly maneuvered to keep less expensive versions of a lifesaving drug out of the hands of millions of Americans,” New York Attorney General Letitia James said in a statement. “Indivior’s drug was supposed to help many, but its monopolistic practices helped fuel the opioid epidemic and impede efforts to confront it. This agreement continues our efforts to address the opioid crisis and hold all the companies that contributed to this crisis accountable.”
New York is expected to retain roughly $5.7 million of that amount, James said.
Under the terms of the deal, Indivior must also inform the AGs of all citizen petitions it submits to the Food and Drug Administration (FDA). The company also has to provide notice about new products and corporate changes to help prevent future monopolistic practices.
The settlement finalized and announced on Friday puts an end to roughly seven years of legal wrangling.
